Compare JPMorgan Chase & Co (JPM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Novo Nordisk A/S — how do they compare? JPMorgan Chase & Co trades at $333.32 (market cap $880.98B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: JPMorgan Chase & Co is far larger — about 5.3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Novo Nordisk A/S for 116 Days on average.
| JPM | NVO | |
|---|---|---|
Market Cap | $880.98B | $165.31B |
Volume | 7,721,661 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $365.18 | $63.98 |
52-Week Low | $282.84 | $35.29 |
Typical Hold Time | 127 Days | 116 Days |
Enterprise Value | $1.82T | $179.56B |
Dividend Yield | 1.99% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $332.39, up 0.85% daily, with a bearish technical signal but strong fundamentals. Recent earnings show two beats out of three reported quarters, with Q3 2026 results pending. Revenue grew to $181.85B in 2025, though net income dipped to $57.05B. The stock is supported by a high ROE of 18.43% and a moderate P/E of 14.2, while analyst consensus is a 'Moderate Buy' with a $373.18 price target.
Outlook remains positive due to solid profitability and institutional support, but risks include geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flows. The stock offers value relative to peers, with upside potential if earnings momentum continues, though investors should monitor macroeconomic headwinds and upcoming Q3 earnings for direction.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
